Previous studies have identified high expression of B7H3 as an adverse factor in multiple tumors, including AML (32, 33), having an immunological function, acting essentially as a coinhibitory immune checkpoint with an important role in immune editing and immune evasion. Here, CD276 is linked to acute myeloid leukemia.